A more effective vaccine technology may be on the horizon. In a new study in mice, researchers from the University of ...

Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...

Robert Malone, who believes the U.S. government has “reality-bending information-control capabilities,” will guide the future ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

Researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering have developed a compound that could work as a ...

The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®. The new vaccine is indicated for active immunization to prevent COVID-19 caused by SARS ...

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.

Researchers identify SARS-CoV-2`s protective mechanism, offering potential targets for new Covid therapies and vaccine ...